Genomic DNA at programmable loci (gDNA)

Genomic DNA at programmable loci refers to specific sequences within the human genome that are targeted for therapeutic modification using precision molecular tools such as CRISPR-Cas9, TALENs, or Zinc Finger Nucleases (Doudna & Charpentier, 2012). Unlike traditional drug targets like proteins or enzymes, this target consists of the primary genetic material itself, allowing for permanent or semi-permanent alterations to gene expression or function (FDA, 2023). In therapeutic applications, these loci are selected based on their role in disease pathology, such as the BCL11A enhancer for sickle cell disease or specific oncogenic mutations in cancer (Frangoul et al., 2021). By binding to these sites, programmable therapies can correct deleterious mutations, disrupt harmful genes, or insert functional genetic sequences. This approach represents a paradigm shift in medicine, moving from treating symptoms to addressing the underlying genetic cause of disease. However, the precision of targeting and the potential for off-target effects remain critical considerations for clinical safety and efficacy (Fu et al., 2013). The development of base and prime editing technologies further expands the utility of this target by allowing for single-nucleotide changes without double-strand breaks (Anzalone et al., 2019).

Other names

Target DNAChromosomal DNAProgrammable DNA sequencesGene lociGenomic DNA

Site-specific DNA modification using programmable nucleases (e.g., CRISPR-Cas9, TALENs, ZFNs) or base/prime editors to induce double-strand breaks or precise chemical modifications, enabling gene knockout, correction, or insertion (Doudna & Charpentier, 2012; FDA, 2023).